HIGH EFFICACY OF THE COMBINATION CHEMOTHERAPY (CT) OF ORAL VINORELBINE (NVBO) AND CAPECITABINE (X) WITH TRASTUZUMAB (H) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): UPDATED ANALYSIS OF THE RESULTS OF AN INTERNATIONAL PHASE II TRIAL

被引：0
|
作者：
Chan, A. [1 ]
Ganju, V. [2 ]
Becquart, D. [3 ]
Conte, P. [4 ]
Gil, M. Gil [5 ]
Petruzelka, L. [6 ]
Bernardo, G. [7 ]
Villanova, G. [8 ]
Tubiana-Mathieu, N. [9 ]
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Frankston Hosp, Melbourne, Vic, Australia
[3] AZ Middelheim, Med Oncol, Antwerp, Belgium
[4] Univ Modena, Univ Hosp, Dept Onc & Hem, I-41100 Modena, Italy
[5] ICO Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain
[6] Gen Fac Hosp, Prague 2, Czech Republic
[7] Fdn S Maugeri, Pavia, Italy
[8] Pierre Fabre Med, Med Affairs Onclo, Boulogne Billancourt, France
[9] CHU Dupuytren, Limoges, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [31] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
    He, Maiyue
    Liu, Jiaxuan
    Wang, Zijing
    Ma, Fei
    Wang, Jiayu
    Zhang, Pin
    Li, Qing
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Mo, Hongnan
    Lan, Bo
    Li, Qiao
    Xu, Binghe
    BREAST, 2023, 72
  • [33] Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
    Schilling, G.
    Bruweleit, M.
    Harbeck, N.
    Thomssen, C.
    Becker, K.
    Hoffmann, R.
    Villena, C.
    Schuette, M.
    Hossfeld, D. K.
    Bokemeyer, C.
    de Wit, M.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 166 - 172
  • [34] Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
    G. Schilling
    M. Bruweleit
    N. Harbeck
    C. Thomssen
    K. Becker
    R. Hoffmann
    C. Villena
    M. Schütte
    D. K. Hossfeld
    C. Bokemeyer
    M. de Wit
    Investigational New Drugs, 2009, 27 : 166 - 172
  • [35] Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Kang, Irene
    Spicer, Darcy V.
    Lu, Janice M.
    Groshen, Susan G.
    Tsao-Wei, Denice
    Garcia, Agustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [37] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [38] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
  • [39] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [40] Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy
    Gelmon, K. A.
    Fumoleau, P.
    Verma, S.
    Wardley, A. M.
    Conte, P. F.
    Miles, D.
    Gianni, L.
    McNally, V. A.
    Ross, G.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345